Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 98.32B +13.4% |
| Revenue (ttm) | 42.05B +1.8% |
| Net Income | 6.31B +34.3% |
| EPS | 3.10 +33.7% |
| Shares Out | n/a |
| PE Ratio | 15.58 |
| Forward PE | 9.12 |
| Dividend | 2.14 (4.45%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 533 |
| Average Volume | 1,416 |
| Open | 48.15 |
| Previous Close | 48.22 |
| Day's Range | 47.73 - 48.29 |
| 52-Week Range | 36.60 - 54.02 |
| Beta | 0.26 |
| RSI | 41.31 |
| Earnings Date | Apr 30, 2026 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
News
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Pr...
Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up
U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 bill...
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to ad...
China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
China's Jiangsu Hengrui Pharmaceuticals said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to develop 13 early‑stage on...
Bristol Myers announces EU approved Sotyktu to treat PsA
Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Sotyktu, or deucravacitinib, alone or in combination with methotrexate, for the treatment of active psoriatic ...
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.
Bristol Myers using AI to boost drug production volume, NY Times reports
Bristol Myers (BMY)’ Massachusetts facility boosted drug production volume for clinical and commercial use by about 40% with AI, The New York Times’ Farah Stockman reports. “We are able to…
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.
Bristol-Myers Squibb Company Transcript: AGM 2026
The meeting reviewed strong 2025 financials, highlighted a robust growth portfolio, and outlined strategic investments in AI and acquisitions. All board proposals passed with high support, while a shareholder proposal for an independent chair was rejected. Patent cliffs and stock underperformance were key risks discussed.
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Bristol Myers price target raised to $66 from $64 at Citi
Citi raised the firm’s price target on Bristol Myers (BMY) to $66 from $64 and keeps a Neutral rating on the shares. The firm updated the company’s model post the…
Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% revenue growth to $11.5B, with a 9% rise in the growth portfolio and strong launches for key assets. Pipeline advanced with regulatory milestones and positive pivotal data, while guidance was reaffirmed and performance is tracking toward the upper end of ranges.
Bristol Myers Squibb Logs Higher Sales, Profit
Bristol Myers Squibb posted higher first-quarter revenue boosted by its portfolio of newer treatments for heart and blood conditions.
Options Volatility and Implied Earnings Moves Today, April 30, 2026
Today, several major companies are expected to report earnings: Altria Group (MO), Apple (AAPL), Bristol-Myers Squibb (BMY), Caterpillar (CAT), Eli Lilly & Co (LLY), Mastercard (MA), Merck & Company (...
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by better-than-expected growth of blood thinner Eliquis as well as newer cancer medicines.
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2026.
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood thinner through billionaire entrepreneur Mark Cuban's online pharmacy beginning April 27.
Bristol Myers-Pfizer Alliance launch collaboration with Mark Cuban for Eliquis
The Bristol Myers Squibb-Pfizer (BMY) – Pfizer (PFE) Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis, or apixaban, on CostPlusDrugs.com. Eliqui...
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company.
Atrium Therapeutics earns $15M development milestone payment from Bristol Myers
Atrium Therapeutics (RNA) has earned a $15M development milestone payment from Bristol Myers (BMY). The milestone was achieved upon the successful delivery of a development candidate for the first lic...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...
Foundation Medicine expands collaboration with Bristol Myers
Foundation Medicine announced an expansion to its collaboration with Bristol Myers (BMY) Squibb to develop FoundationOneCDx as a next-generation sequencing-based companion diagnostic to identify patie...
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOn...